News

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance…
Read More...

WuXi Biologics has stepped up its efforts in enabling the development of multiple neutralizing antibodies for Novel Coronavirus (2019-nCoV) with its integrated technology platforms.…
Read More...

Conatus Pharmaceuticals Inc. and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body,…
Read More...

TILT Biotherapeutics announces that they have signed a license agreement with Biotheus Inc. (“Biotheus”), a privately held Chinese company based in Zhuhai, Guangdong, China. Under the…
Read More...

Roche announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination…
Read More...

Merck, known as MSD outside the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for DIFICID (fidaxomicin) for…
Read More...

AbbVie and Allergan announced that Allergan has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase). These agreements are in conjunction…
Read More...

EyePoint Pharmaceuticals and Ocumension Therapeutics announced an exclusive license agreement for the development and commercialization of DEXYCU (dexamethasone intraocular suspension)…
Read More...

Bionetix, a biotech company developing novel oncology drugs; ProQinase, an oncology-focused contract research organization (CRO) recently acquired by Reaction Biology Corporation…
Read More...

Pelican BioThermal announced the further expansion of its worldwide reach into Australia and New Zealand, effective immediately. Wilpak Group International will provide sales and…
Read More...

ATAI Life Sciences AG announced an investment in two separate joint ventures (JV) with DemeRx, a clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for…
Read More...

Genialis announced a collaborative partnership with Oncologie, an international, clinical-stage biopharma developing next-generation immunotherapies for cancer. Initial activities will…
Read More...

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. for $68 per share in cash. “The acquisition of Synthorx perfectly aligns with our R&D strategy,…
Read More...

Evotec SE and Indivumed GmbH announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of…
Read More...

Moderna, Inc. a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and…
Read More...

Catalent welcomed the news that DiaMedica Therapeutics has received U.S. Food and Drug Administration (FDA) approval to commence Phase 2 clinical trials of its lead candidate, DM199,…
Read More...

Roche announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA). The…
Read More...

Epizyme, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TAZVERIK (tazemetostat) for the treatment of adults and pediatric patients…
Read More...

INHIBITOR Therapeutics, Inc. a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous and…
Read More...

Roche announced that the European Commission has granted conditional marketing authorisation for Polivy (polatuzumab vedotin), in combination with bendamustine plus MabThera (rituximab)…
Read More...